ライフサイエンスコーパス: intensive chemotherapy

1 d (556 on intensive chemotherapy, 423 on non-intensive chemotherapy).

2 irradiation, and ABMT versus three cycles of intensive chemotherapy.

3 onfers a poor prognosis with use of standard intensive chemotherapy.

4 four cycles of cyclophosphamide-based, dose-intensive chemotherapy.

5 patients who are unlikely to survive despite intensive chemotherapy.

6 therapies, including surgery, radiation, and intensive chemotherapy.

7 them were treated with brief (<4 months) but intensive chemotherapy.

8 ter mobilization with either intermediate or intensive chemotherapy.

9 et transfusions in patients who undergo dose-intensive chemotherapy.

10 ndrome, were nonrandomly assigned to receive intensive chemotherapy.

11 reatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy.

12 s with newly diagnosed AML who are unfit for intensive chemotherapy.

13 ing the traditional notion of 2.5-3 years of intensive chemotherapy.

14 ute myeloid leukemia (AML) largely relies on intensive chemotherapy.

15 C) (n = 74) for patients with AML undergoing intensive chemotherapy.

16 hase chronic myeloid leukaemia, suitable for intensive chemotherapy.

17 hase chronic myeloid leukaemia, suitable for intensive chemotherapy.

18 ute myeloid leukaemia who are ineligible for intensive chemotherapy.

19 se with hematological malignancies or during intensive chemotherapy.

20 eatment with midostaurin in combination with intensive chemotherapy.

21 (range, 18-80) and 94% had received previous intensive chemotherapy.

22 ive form of leukemia that currently requires intensive chemotherapy.

23 or AML patients 60 years of age treated with intensive chemotherapy.

24 based on data from younger adults receiving intensive chemotherapy.

25 s very high-risk group of patients receiving intensive chemotherapy.

26 o have obtained a complete remission (CR) on intensive chemotherapy.

27 mproved with the combination of imatinib and intensive chemotherapy.

28 tic AML plasma samples before treatment with intensive chemotherapy.

29 patients and those more appropriate for non-intensive chemotherapy.

30 aive elderly patients unfit for conventional intensive chemotherapy.

31 e myeloid leukaemia who are not eligible for intensive chemotherapy.

32 treatment-naive AML and were ineligible for intensive chemotherapy.

33 -IDH2 acute myeloid leukaemia ineligible for intensive chemotherapy.

34 ions in older adults with AML ineligible for intensive chemotherapy.

35 e myeloid leukemia (AML) who cannot tolerate intensive chemotherapy.

36 treatment for older adults not suitable for intensive chemotherapy.

37 yeloid leukaemia who were not candidates for intensive chemotherapy.

38 ts Of 2,992 patients, 1,588 (53.1%) received intensive chemotherapy.

39 py and to unfit patients, unable to tolerate intensive chemotherapy.

40 ntensity therapy in older patients unfit for intensive chemotherapy.

41 ute myeloid leukemia who were ineligible for intensive chemotherapy.

42 ce host toxicity in patients undergoing dose intensive chemotherapy.

43 CL patients, particularly those treated with intensive chemotherapy.

44 40% of these patients relapse after standard intensive chemotherapy.

45 oid leukemia (AML) is still dismal even with intensive chemotherapy.

46 y diagnosed with non-M3 AML and were fit for intensive chemotherapy.

47 AML) who are 75 years or older, or unfit for intensive chemotherapy.

48 yeloid leukemia (AML) not considered fit for intensive chemotherapy.

49 ermediate-risk cytogenetics AML treated with intensive chemotherapy.

50 ents with malignant hemopathies treated with intensive chemotherapy.

51 ologic features and a poor prognosis despite intensive chemotherapy.

52 We aimed to improve these results using more intensive chemotherapy.

53 tients develop disease that is refractory to intensive chemotherapy.

54 ients older than 60 years who do not receive intensive chemotherapy.

55 patients in terms of quality of life versus intensive chemotherapy.

56 r= 65 years of age and deemed unsuitable for intensive chemotherapy.

57 ) who were not candidates for or who refused intensive chemotherapy.

58 randomly assigned to receive six courses of intensive chemotherapy (117 patients) or autologous tran

59 Despite intensive chemotherapy, 20% of pediatric patients and ov

60 otherapy); and 979 on clodronic acid (556 on intensive chemotherapy, 423 on non-intensive chemotherap

61 is: 981 in the zoledronic acid group (555 on intensive chemotherapy, 426 on non-intensive chemotherap

62 ia) from 1990 to 2006 who received frontline intensive chemotherapy; 723 (47%) were 60 years or older

63 venetoclax plus intensive chemotherapy than intensive chemotherapy (79% [95% CI 67-88] vs 57% [49-65

64 %) >/= 70 years of age with AML is poor with intensive chemotherapy (8-week mortality >/= 30%; median

65 mune effects of the addition of rituximab to intensive chemotherapy, a prespecified secondary aim of

66 Many patients receiving dose-intensive chemotherapy acquire thrombocytopenia and need

67 Despite treatment with intensive chemotherapy, acute myelogenous leukemia (AML)

68 te myeloid leukaemia who were ineligible for intensive chemotherapy (aged >=75 years, an Eastern Coop

69 s in a lower risk of disease recurrence than intensive chemotherapy alone, overall outcome following

70 blastoma cells or to receive three cycles of intensive chemotherapy alone.

71 netoclax plus intensive chemotherapy or with intensive chemotherapy alone.

72 venetoclax plus intensive chemotherapy with intensive chemotherapy alone.

73 lysis focused on adult patients who received intensive chemotherapy and a mold-active AFP for at leas

74 MDS and identifies patients who benefit from intensive chemotherapy and allo-HCT.

75 rrent AML management still relies largely on intensive chemotherapy and allogeneic hematopoietic stem

76 ng the cure rates while reducing reliance on intensive chemotherapy and allogeneic stem-cell transpla

77 sed acute myeloid leukaemia not eligible for intensive chemotherapy and an ECOG performance status of

78 th now prolonged disease-free survival after intensive chemotherapy and anti-CD20-based maintenance.

79 Consolidation was with intensive chemotherapy and autologous bone marrow transp

80 th metastatic neuroblastoma (NB) die despite intensive chemotherapy and bone marrow transplantation.

81 n of long-term complications associated with intensive chemotherapy and cranial irradiation.

82 ) and large-cell lymphoma (LCL) treated with intensive chemotherapy and hematopoietic colony-stimulat

83 This regimen also reduces the need for intensive chemotherapy and HSCT in first remission in th

84 common among children with cancer receiving intensive chemotherapy and in pediatric recipients of he

85 pective and prospective data supporting both intensive chemotherapy and low-intensity venetoclax-base

86 increase in the number of children receiving intensive chemotherapy and marrow transplantation, but a

87 a in newly diagnosed patients ineligible for intensive chemotherapy and patients with relapsed or ref

88 commended for FLT3-ITD-mutated AML following intensive chemotherapy and prior to allogeneic hematopoi

89 uration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic

90 Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effectiv

91 cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1)

92 Intensive chemotherapy and stem cell transplantation in

93 ent lymphoma ranges from watchful waiting to intensive chemotherapy and stem cell transplantation.

94 Despite intensive chemotherapy and surgical resection, approxima

95 marrow can protect mice from time- and dose-intensive chemotherapy and that the combination of 6-BG

96 ng excellent supportive care while receiving intensive chemotherapy and the use of hematopoietic cell

97 ike tyrosine kinase 3 (FLT3) inhibitors with intensive chemotherapy and transplant has substantially

98 ents to other investigational therapies (eg, intensive chemotherapy and/or autologous stem-cell trans

99 ed 18-60 years (or >60 years if suitable for intensive chemotherapy), and had newly diagnosed acute m

100 p (555 on intensive chemotherapy, 426 on non-intensive chemotherapy); and 979 on clodronic acid (556

101 Only 55% of patients received intensive chemotherapy, and 42% of patients underwent st

102 r adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem

103 rapy, treatment of patients not eligible for intensive chemotherapy, and novel agents for relapsed/re

104 chemotherapy; another 22 underwent surgery, intensive chemotherapy, and radiation therapy.

105 emic blasts, increased risk of relapse after intensive chemotherapy, and reduced event-free and overa

106 ther hydroxyurea, hypomethylating agents, or intensive chemotherapy, and stratified by risk according

107 n be administered safely in combination with intensive chemotherapy, and the degree of Bcl-2 downmodu

108 et transfusions in patients who undergo dose-intensive chemotherapy, and thus may permit chemotherapy

109 sed acute myeloid leukaemia not eligible for intensive chemotherapy, and with Eastern Cooperative Onc

110 ia (AML) who are not considered suitable for intensive chemotherapy are limited.

111 features for whom the expected outcomes with intensive chemotherapy are poor.

112 ovudine (probably after 1-2 cycles of CHOP), intensive chemotherapy as in LSG-15 with G-CSF support a

113 ients with AML age >/= 55 years treated with intensive chemotherapy as part of Southwest Oncology Gro

114 This is the first study to show that intensive chemotherapy, as given in the A-BFM regimen, c

115 HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic

116 ning backbone in younger patients, unfit for intensive chemotherapy, as well as comparisons to standa

117 have multiple benefits in patients receiving intensive chemotherapy at high risk for infection.

118 mparing 3 intensive postremission therapies: intensive chemotherapy, autologous transplantation (ABMT

119 Survival after failure of intensive chemotherapy, azacitidine, or decitabine was m

120 is an effective treatment modality, it is an intensive chemotherapy-based therapy with a range of sho

121 sed ALL receiving blinatumomab compared with intensive chemotherapy before hematopoietic stem-cell tr

122 /= 20% blasts) treated with cytarabine-based intensive chemotherapy between 1990 and 2008 to identify

123 After three courses of intensive chemotherapy, bone marrow was harvested from p

124 randomized study comparing standard vs less-intensive chemotherapy, both combined with imatinib, for

125 erapy population includes patients receiving intensive chemotherapy but do not all go on to have an a

126 omas) who are increasingly treated with more intensive chemotherapy, but a more biologically coherent

127 be successfully treated into remission with intensive chemotherapy, but it routinely relapses.

128 ortens the time to neutrophil recovery after intensive chemotherapy, but its role in the treatment of

129 urkitt's lymphoma (BL) can often be cured by intensive chemotherapy, but the toxicity of such therapy

130 We conclude that epigenetic priming of intensive chemotherapy can be safely delivered in an att

131 apy followed by a shortened schedule of dose-intensive chemotherapy can be used to improve the outcom

132 ppear to be suitable (also known as fit) for intensive chemotherapy can have high rates of morbidity

133 After intensive chemotherapy, CD8+ T cells had a faster effect

134 ompared with 86 [61%] of 140 patients in the intensive chemotherapy cohort (odd ratio 3.2 [95% CI 1.5

135 [53%] were women); 85 in the venetoclax plus intensive chemotherapy cohort and 194 in the intensive c

136 (86%) of 74 patients in the venetoclax plus intensive chemotherapy cohort had an MRD-negative compos

137 Patients in the venetoclax plus intensive chemotherapy cohort were matched with patients

138 apy cohort were matched with patients in the intensive chemotherapy cohort.

139 intensive chemotherapy cohort and 194 in the intensive chemotherapy cohort.

140 prove the efficacy and feasibility of short-intensive chemotherapy combined with the anti-CD20 antib

141 Intensive chemotherapy consisted of thiotepa (250 mg/m(2

142 ffective and less toxic therapies, replacing intensive chemotherapy courses and allogeneic stem-cell

143 aggressive B-cell lymphoma curable with dose-intensive chemotherapy derived from pediatric leukemia r

144 In young adults with acute myeloid leukemia, intensive chemotherapy during the initial remission impr

145 with acute myeloid leukemia (AML) receiving intensive chemotherapy experience substantial decline in

146 t one of the criteria defining unfitness for intensive chemotherapy (F-unfit).

147 After intensive chemotherapy, FL levels rose to a mean of 488

148 typically begins with 5 to 9 months of more-intensive chemotherapy followed by a prolonged low-inten

149 ultitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoie

150 after the most important curative approach, intensive chemotherapy followed by allogeneic hematopoie

151 Ninety percent of patients received intensive chemotherapy followed by autologous stem cell

152 characterize early lymphocyte recovery after intensive chemotherapy for acute myelogenous leukemia (A

153 bacterial prophylaxis for children receiving intensive chemotherapy for acute myeloid leukemia and re

154 Adults who received intensive chemotherapy for ALL benefited from G-CSF trea

155 The addition of more intensive chemotherapy for anaplastic histology disease,

156 o-treat analysis: 36 +/- 5.8 percent for the intensive-chemotherapy group as compared with 38 +/- 6.4

157 urvival at three years for the nonrandomized intensive-chemotherapy group was 39 +/- 5.1 percent, and

158 with autologous transplantation than in the intensive-chemotherapy group.

159 Venetoclax combined with intensive chemotherapy has been shown to be safe with pr

160 ed acute myeloid leukemia (AML) treated with intensive chemotherapy; however, there are no data regar

161 Patients received four cycles of intensive chemotherapy (hyper-CVAD [hyperfractionated cy

162 acute myeloid leukemia (AML) ineligible for intensive chemotherapy (IC) have limited treatment optio

163 ated acute myeloid leukemia (AML) treated by intensive chemotherapy (IC), prognostic significance of

164 ns are approved in the frontline setting for intensive chemotherapy (IC)-ineligible AML: venetoclax (

165 f life (HRQoL) outcomes than those receiving intensive chemotherapy (IC).

166 ylating agents (azacitidine and decitabine), intensive chemotherapy (ICT), and allogeneic stem-cell t

167 For patients who had not received prior intensive chemotherapy (ie, with secondary AML or high-r

168 Venetoclax plus intensive chemotherapy improved event-free survival (med

169 The addition of rituximab to intensive chemotherapy improves outcomes in patients wit

170 utcome of 86 of these patients, treated with intensive chemotherapy in 5 prospective Acute Leukemia F

171 POCH-R) may obviate the need for highly dose-intensive chemotherapy in adults with Burkitt lymphoma.

172 Crenolanib plus intensive chemotherapy in adults with newly diagnosed FL

173 We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed FL

174 d efficacy of venetoclax in combination with intensive chemotherapy in AML is unknown.

175 Determining fitness for intensive chemotherapy in an older adult with acute myel

176 Sustained EFS and OS can be achieved with intensive chemotherapy in children and young adults with

177 a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CY

178 second-generation ABL-class inhibitor, with intensive chemotherapy in children with newly diagnosed

179 B-cell neoplasm that is currently treated by intensive chemotherapy in combination with anti-CD20 ant

180 ve as a benchmark for expected outcomes with intensive chemotherapy in F-fit and F-unfit patients.

181 g the role of venetoclax in combination with intensive chemotherapy in fitter patients with AML.

182 In conclusion, the addition of GO to intensive chemotherapy in NPM1mut AML resulted in a sign

183 is associated with similar survival rates as intensive chemotherapy in older patients with newly diag

184 ate the activity of venetoclax combined with intensive chemotherapy in patients aged 65 years or youn

185 cy of ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed

186 Although generally curable with intensive chemotherapy in resource-rich settings, Burkit

187 trans retinoic acid (RA) in combination with intensive chemotherapy is associated with leukemic cellu

188 t azacitidine maintenance after CR/CRi after intensive chemotherapy is feasible and significantly imp

189 Determination of patient fitness for intensive chemotherapy is imperfect, and even older pati

190 Rapid recovery of CD4+ T cells after intensive chemotherapy is limited by an age-dependent de

191 te myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse an

192 y these Ferrara criteria predict fitness for intensive chemotherapy is unknown.

193 l-known life-threatening complication during intensive chemotherapy, its incidence, impact and outcom

194 After postremission therapy including intensive chemotherapy (n = 121) or autologous hematopoi

195 t our institution between 2000 and 2010 with intensive chemotherapy (n = 557) or azacitidine- or deci

196 igh-risk DDX41 MDS/AML patients treated with intensive chemotherapy (n = 9) or azacitidine (n = 11) h

197 re is increasing evidence that prolonged and intensive chemotherapy often fails to eradicate leukemic

198 Patients with MDS or AML after either intensive chemotherapy only or consecutive allogeneic st

199 Other patients may receive intensive chemotherapy or autologous transplantation; we

200 emia who achieved long-term remissions after intensive chemotherapy or bone marrow transplantation (B

201 ch represents a shift from the paradigm that intensive chemotherapy or radiotherapy, or both, is need

202 fractory mantle cell lymphoma ineligible for intensive chemotherapy or stem-cell transplantation have

203 e-threatening hematologic disorders received intensive chemotherapy or total-body irradiation and the

204 e and cytarabine either with venetoclax plus intensive chemotherapy or with intensive chemotherapy al

205 h acute myeloid leukaemia but unsuitable for intensive chemotherapy (or <60 years if unsuitable for i

206 ts, many older patients are not suitable for intensive chemotherapy owing to comorbidities or general

207 Despite intensive chemotherapy plus trastuzumab for patients wit

208 went a significant change in 1988 when a new intensive chemotherapy program was introduced (CALGB 881

209 er autologous bone marrow transplantation or intensive chemotherapy prolongs event-free survival equa

210 We aimed to assess whether an intensive chemotherapy protocol that had a 10-day interv

211 ogress has been made in tailoring moderately intensive chemotherapy protocols for Philadelphia chromo

212 sk patients, primarily due to the failure of intensive chemotherapy protocols to deplete LSCs and tox

213 In conclusion, combining lestaurtinib with intensive chemotherapy proved feasible in younger patien

214 tcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited.

215 tion of selective TKIs with or without prior intensive chemotherapy, rarely local radiotherapy, and/o

216 o middle-aged adults who receive a pediatric-intensive chemotherapy regimen for treatment of Philadel

217 nal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated

218 ly reported a high response rate with a dose-intensive chemotherapy regimen in 24 children with high-

219 coma Intergroup (EOI) suggested that a short intensive chemotherapy regimen with doxorubicin and cisp

220 ll achieve durable remission with this brief intensive chemotherapy regimen.

221 be treated as cytogenetic high risk, receive intensive chemotherapy (regimen C), and will only be rec

222 ildren with HR-ALL were randomly assigned to intensive chemotherapy regimens (New York I [NY I] or NY

223 omes for adolescents and young adults, these intensive chemotherapy regimens are not well tolerated i

224 Intensive chemotherapy regimens have led to a substantia

225 We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated

226 al was superior among those who had received intensive chemotherapy regimens instead of lower-dose re

227 Current treatments, based on intensive chemotherapy regimens provide overall survival

228 Intensive chemotherapy regimens result in cure rates >85

229 Because intensive chemotherapy regimens used in most childhood c

230 The intensive chemotherapy regimens used to treat acute myel

231 mia (ALL) now achieve remission with current intensive chemotherapy regimens.

232 ommended for patients receiving IFL or other intensive chemotherapy regimens.

233 , respectively) after the change to the more intensive chemotherapy regimens.

234 Although intensive chemotherapy remains the mainstay of acute mye

235 marily, we consider age, fitness to tolerate intensive chemotherapy, remission duration, and presence

236 he most toxic elements of currently deployed intensive chemotherapy schedules with their associated u

237 ) with newly diagnosed AML, not eligible for intensive chemotherapy; secondary AML (progressed after

238 Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acut

239 in (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group).

240 ight randomized, active-controlled trials of intensive chemotherapy submitted to the US Food and Drug

241 ddition of autologous BMT to four courses of intensive chemotherapy substantially reduces the risk of

242 away from uniform approaches based solely on intensive chemotherapy (such as '7 + 3') toward personal

243 ing patients was higher with venetoclax plus intensive chemotherapy than intensive chemotherapy (79%

244 iagnosed in the first trimester necessitates intensive chemotherapy that is likely to induce fetal ma

245 leukemia (AML) requires multiple courses of intensive chemotherapy that result in neutropenia, with

246 ferative B-cell neoplasm and is treated with intensive chemotherapy that, because of its toxicity, is

247 e safety and activity of venetoclax added to intensive chemotherapy (the CLIA regimen [cladribine, hi

248 ssification systems are based on response to intensive chemotherapy; their ability to discriminate ou

249 a was given as replacement for postremission intensive chemotherapy to patients with chemotherapy int

250 h effective alternative therapies to current intensive chemotherapy treatments have yet to be develop

251 The introduction of intensive chemotherapy treatments together with patient

252 cutive prospective, randomized, multicenter, intensive chemotherapy trials (AML96, AML2003) from the

253 1.16-2.05]; p=0.0027) for those treated with intensive chemotherapy versus hypomethylating agents.

254 14.8-21.5; HR 1.44 [1.02-2.03]; p=0.040) for intensive chemotherapy versus hypomethylating agents.

255 Although intensive chemotherapy was historically considered the o

256 ly patients with AML who were unsuitable for intensive chemotherapy was manageable and typical of a c

257 ic recovery (CRi) after at least 2 cycles of intensive chemotherapy, we assessed the value of azaciti

258 60 years if monosomal karyotype) and fit for intensive chemotherapy were allocated to venetoclax dose

259 0 years with newly diagnosed AML and planned intensive chemotherapy were enrolled at a single institu

260 with previously untreated AML ineligible for intensive chemotherapy were enrolled.

261 s represents the most common complication of intensive chemotherapy, which has a severe adverse impac

262 proximately 10% of AML patients treated with intensive chemotherapy, which to a large extent can be p

263 >=55 years with AML in first remission after intensive chemotherapy who were not candidates for hemat

264 chemotherapy (or <60 years if unsuitable for intensive chemotherapy with an anthracycline plus cytara

265 gery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transpl

266 s to compare the activity of venetoclax plus intensive chemotherapy with intensive chemotherapy alone

267 Dose-intensive chemotherapy with intravenous melphalan and gr

268 health and to maintain high cure rates, dose-intensive chemotherapy with limited cumulative doses was

269 val than that of older children treated with intensive chemotherapy with or without ABMT.

270 eat FN and to assist patients receiving dose-intensive chemotherapy with or without stem cell support

271 openia and to assist patients receiving dose-intensive chemotherapy with or without stem cell support

272 ropenia or to assist patients receiving dose-intensive chemotherapy with or without stem cell support

273 Most importantly, intensive chemotherapy with or without stem cell transpl

274 Dose-intensive chemotherapy with vincristine, doxorubicin, cy

275 All patients were treated with intensive chemotherapy, with or without haemopoietic ste

276 nts with ALL can be cured with risk-adjusted intensive chemotherapy without stem-cell transplantation